Madrigal Pharmaceuticals, Inc. has promoted Rebecca Taub, M.D., to the newly created position of President of Research & Development. 
 
Dr. Taub has served as Chief Medical Officer and Executive Vice President of Research & Development, of Madrigal  since 2016. She is also a member of the Company’s Board of Directors.
 
Paul Friedman, M.D., Chairman and CEO of Madrigal, stated, “As we continue to advance resmetirom forward in Phase 3 clinical development in both NASH and earlier stage NASH/NAFLD patients with dyslipidemias, and as we seek to add to the professional resources of the Company, Becky’s leadership as President of R&D promises to be of great value to all of our key stakeholders.”